Tengmai Medicine receives $22 million in additional Series A round financing.

On November 14th, Tengmai Medicine announced the completion of a $22 million Series A additional financing to expand its globally leading drug discovery platform. This round of financing was jointly led by new investors Yicun Capital and Chipower Venture, with existing investors Orbimed Capital and Qiming Venture as well as Capital and Sequoia Capital participating in the follow-up investment. According to Tengmai Medicine, since its establishment in 2022, its cumulative financing amount has exceeded $80 million.